Prevalence of IgG Antibodies Directed at 8 Leukemia-Derived Antigens (P Value Compared With CML Patients)
| Diagnosis . | Antigen . | |||||||
|---|---|---|---|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | 5 . | 6 . | 7 . | 8 . | |
| CML | 9/15 | 9/15 | 8/15 | 8/15 | 9/15 | 11/15 | 8/15 | 9/15 |
| Normal | 2/24 (P < .01) | 2/24 (P < .01) | 2/24 (P < .01) | 2/24 (P < .01) | 9/24 NS | 2/24 (P < .001) | 2/24 (P < .01) | 1/24 (P < .01) |
| Other hematological malignancies | 7/38 (P < .01) | 7/38 (P < .01) | 7/38 (P < .01) | 7/38 (P < .01) | 8/38 (P < .02) | 7/38 (P < .001) | 7/38 (P < .01) | 7/38 (P < .01) |
| Diagnosis . | Antigen . | |||||||
|---|---|---|---|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | 5 . | 6 . | 7 . | 8 . | |
| CML | 9/15 | 9/15 | 8/15 | 8/15 | 9/15 | 11/15 | 8/15 | 9/15 |
| Normal | 2/24 (P < .01) | 2/24 (P < .01) | 2/24 (P < .01) | 2/24 (P < .01) | 9/24 NS | 2/24 (P < .001) | 2/24 (P < .01) | 1/24 (P < .01) |
| Other hematological malignancies | 7/38 (P < .01) | 7/38 (P < .01) | 7/38 (P < .01) | 7/38 (P < .01) | 8/38 (P < .02) | 7/38 (P < .001) | 7/38 (P < .01) | 7/38 (P < .01) |
Abbreviation: NS, not significant.